{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T03:57:22Z","timestamp":1777348642661,"version":"3.51.4"},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100010318","name":"University of Manitoba","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010318","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.diagmicrobio.2021.115418","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T15:16:10Z","timestamp":1620314170000},"page":"115418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["In vitro activity of imipenem-relebactam against various resistance phenotypes\/genotypes of Enterobacterales and Pseudomonas aeruginosa isolated from patients across Canada as part of the CANWARD study, 2016-2019"],"prefix":"10.1016","volume":"101","author":[{"given":"Andrew","family":"Walkty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James A.","family":"Karlowsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie R.","family":"Baxter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather J.","family":"Adam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyssa","family":"Golden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Lagace-Wiens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George G.","family":"Zhanel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2021.115418_bib0001","doi-asserted-by":"crossref","first-page":"iv64","DOI":"10.1093\/jac\/dkz289","article-title":"Dramatic rise in the proportion of ESBL-producing `Escherichia coli and Klebsiella pneumoniae among clinical isolates identified in Canadian hospital laboratories from 2007 to 2016","volume":"74","author":"Denisuik","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2021.115418_bib0002","first-page":"165","article-title":"Vital signs: carbapenem-resistant Enterobacteriaceae","volume":"62","author":"Centers for Disease Control and Prevention (CDC)","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.diagmicrobio.2021.115418_bib0003","doi-asserted-by":"crossref","first-page":"iii2","DOI":"10.1093\/jac\/dky027","article-title":"Treatment of infections caused by multidrug-resistant Gram-negative bacteria: Report of the British Society for Antimicrobial Chemotherapy\/Healthcare Infection Society\/British Infection Association Joint Working Party","volume":"73","author":"Hawkey","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2021.115418_bib0004","series-title":"Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases","first-page":"285","article-title":"Ertapenem, imipenem, meropenem, doripenem, and aztreonam","author":"Doi","year":"2020"},{"key":"10.1016\/j.diagmicrobio.2021.115418_bib0005","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/phar.2378","article-title":"Imipenem-cilastatin-relebactam: a novel \u03b2-lactam-\u03b2-lactamase inhibitor combination for the treatment of multidrug-resistant Gram-negative infections","volume":"40","author":"Smith","year":"2020","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.diagmicrobio.2021.115418_bib0006","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40265-017-0851-9","article-title":"Imipenem-relebactam and meropenem-vaborbactam: two novel carbapenem-\u03b2-lactamase inhibitor combinations","volume":"78","author":"Zhanel","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.diagmicrobio.2021.115418_bib0007","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1093\/jac\/dkx139","article-title":"Prospective, randomized, double-blind, phase 2 dose-ranging study comparing efficacy and safety of imipenem\/cilastatin plus relebactam with imipenem\/cilastatin alone in patients with complicated urinary tract infections","volume":"72","author":"Sims","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2021.115418_bib0008","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1128\/AAC.00633-16","article-title":"Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection","volume":"60","author":"Lucasti","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2021.115418_bib0009","series-title":"RecarbrioTM (imipenem, cilastatin, and relebactam) for injection, for intravenous use, highlights of prescribing information","author":"Sharp","year":"2020"},{"key":"10.1016\/j.diagmicrobio.2021.115418_bib0010","series-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically","author":"Clinical and Laboratory Standards Institute","year":"2018"},{"key":"10.1016\/j.diagmicrobio.2021.115418_bib0011","series-title":"Performance Standards for Antimicrobial Susceptibility Testing","author":"Clinical and Laboratory Standards Institute","year":"2020"},{"key":"10.1016\/j.diagmicrobio.2021.115418_bib0012","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2021.115418_bib0013","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jgar.2019.10.028","article-title":"In vitro activity of imipenem\/relebactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples: SMART surveillance United States 2015-2017","volume":"21","author":"Karlowsky","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.diagmicrobio.2021.115418_bib0014","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.diagmicrobio.2019.05.001","article-title":"Activity of imipenem-relebactam against multidrug-resistant Pseudomonas aeruginosa from the United States \u2013 SMART 2015-2017","volume":"95","author":"Karlowsky","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2021.115418_bib0015","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1093\/jac\/dkz191","article-title":"Activity of imipenem\/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015-17","volume":"74","author":"Lob","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2021.115418_bib0016","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1099\/jmm.0.001142","article-title":"In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples \u2013 SMART surveillance Europe 2015-2017","volume":"69","author":"Lob","year":"2020","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.diagmicrobio.2021.115418_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2019.10.022","article-title":"In-vitro activity of imipenem\/relebactam and key \u03b2-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients \u2013 SMART surveillance United States 2015-2017","volume":"55","author":"Karlowsky","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2021.115418_bib0018","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2021.115418_bib0019","doi-asserted-by":"crossref","first-page":"6787","DOI":"10.1128\/AAC.01359-16","article-title":"Results from the Canadian Nosocomial Infection Surveillance Program on carbapenemase-producing Enterobacteriaceae, 2010 to 2014","volume":"11","author":"Mataseje","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2021.115418_bib0020","first-page":"2286","article-title":"Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa","volume":"68","author":"Livermore","year":"2013","journal-title":"J Antimicrob Chemother"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889321001115?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889321001115?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:55:51Z","timestamp":1760003751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889321001115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0732889321001115"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2021.115418","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of imipenem-relebactam against various resistance phenotypes\/genotypes of Enterobacterales and Pseudomonas aeruginosa isolated from patients across Canada as part of the CANWARD study, 2016-2019","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2021.115418","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115418"}}